摘要
目的:了解中国良性前列腺增生(BPH)患者用药情况。方法:采用横断面调查的方法,对中国11个城市33个三级甲等医院门诊BPH患者用药情况进行调查。结果:5α-还原酶抑制剂非那雄胺在患者中采用百分比为最高(48.0%)。其次为-受体阻滞剂坦索罗辛(22.7%)。结论:研究结果可能会为临床BPH诊疗及治疗BPH药品的市场开发提供参考。
Objective：To probe into the general information of drugs for benign prostatic hyperplasia. Methods： This cross-sectional study was performed in 33 medical centers located in 11 different cities in China. A survey investigated BPH patients who were asked to record their preferences in drugs. Results： 5-reductase inhibitor Finasteride was the most prescribed medication（48.0%）, followed by -adrenoeeptor antagonists Terazosin （22.7%）. Conclusions： The study may also provides reference for the China BPH clinical practice and the BPH drug market.
出处
《北方药学》
2012年第9期81-82,共2页
Journal of North Pharmacy
关键词
良性前列腺增生
药物
调查
Benign prostatic hyperplasia Drug Investigation
